LEQEMBI IQLIK(R) (lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer’s Disease
TOKYO and CAMBRIDGE, Mass., August 27, 2026 – (JCN Newswire) –Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB, revealed today that as soon as weekly lecanemab-irmb subcutaneous injection (trademark name: LEQEMBI IQLIK ®)is now readily available in the U.S. for initiation treatment for early Alzheimer’s illness (ADVERTISEMENT) in grownups with moderate cognitive disability (MCI) or moderate dementia due to advertisement, jointly described as early advertisement.
LEQEMBI IQLIK is administered through an autoinjector, presenting a practical option to intravenous (IV) dosing from the start of treatment. For initiation, the accepted routine is 500 mg provided when weekly as 2 successive 250 mg injections, each provided in around 15 seconds. LEQEMBI IQLIK might likewise be utilized for upkeep dosing at 360 mg when weekly after 18 months of IV or subcutaneous (SC) treatment. Throughout the whole treatment course– from initiation through upkeep– clients might get LEQEMBI either as IV infusion or as SC injection with LEQEMBI IQLIK. Clients might likewise change from IV to SC administration, or vice versa, supplying higher benefit and versatility in LEQEMBI administration.
Broadening Treatment Convenience and Flexibility Across the Alzheimer’s Disease Care Pathway
The accessibility of LEQEMBI IQLIK for both initiation and upkeep treatment in the U.S. improves treatment benefit and versatility, using early advertisement clients and their care partners more control in handling their care while decreasing barriers to starting and continuing treatment with LEQEMBI. LEQEMBI IQLIK might decrease the time invested getting anti-amyloid treatment by means of IV infusions. In addition, at-home administration enables clients and their care partners to continue treatment without the concern of center sees, making it simpler to head out and travel. LEQEMBI IQLIK likewise has the prospective to decrease health care resources connected with IV dosing, suchas infusion preparation and nurse tracking. These functions might assist simplify the general advertisement treatment path. For ARIA tracking, similar to IV administration, brain magnetic resonance imaging (MRI) is carried out prior to starting treatment and at defined time points after treatment initiation.
Assistance Resources for LEQEMBI IQLIK
Eisai and Biogen will offer a series of resources to assist clients, care partners, doctor, health systems and drug stores effectively carry out and utilize LEQEMBI IQLIK.
Client Support
Resources consist of an Instructions for Use (IFU) video and IQLIK Welcome Kit. The IQLIK Welcome Kit supplies a What to Expect Treatment Tracker, an injection suggestion magnet, and a Demo Kit to assist clients and care partners comprehend what to anticipate, get ready for at-home injections, and administer injections securely in your home. The LEQEMBI Companion ® app will likewise be readily available. It brings the details clients and care partners require into one experience, consisting of education about the injection procedure and tools for tracking each dosage.
Through the LEQEMBI Specialty Pharmacy Network, clients might get assistance with prescription satisfaction, insurance protection navigation, onboarding, shipment coordination, device-use education, and– if they pick to get involved– treatment tips and instructional assistance throughout the very first 6 months of treatment. Clients utilizing other qualified specialized drug stores might have access to comparable assistance, which might differ by drug store.
Doctor Resources
Electronic Health Record (EHR) assistance products and a detailed Getting Started Guide will assist companies browse the procedure from prescription submission through treatment initiation.
Financial Assistance
To even more support access to LEQEMBI for particular clients who require assistance spending for their medications, Eisai’s Patient Assistance Program (PAP) will offer LEQEMBI and LEQEMBI IQLIK at no charge, for qualified uninsured clients, who fulfill monetary requirement and other program requirements.
* The LEQEMBI Companion app was established to provide behavior-driven digital assistance for clients andcare partners along their treatment journey, in collaboration with Medisafe Ltd., a behavioral client engagement engine constructed for complex and specialized treatments. Clients can go to LEQEMBI.com/ CompanionAppSignUp to get going.
Eisai functions as the lead for lecanemab’s advancement and regulative submissions internationally with Eisai and Biogen co-commercializing and co-promoting the item and Eisai having last decision-making authority.
SIGN
LEQEMBI ® is shown for the treatment of Alzheimer’s illness (ADVERTISEMENT). Treatment with LEQEMBI need to be started in clients with moderate cognitive disability (MCI) or moderate dementia phase of illness, the population in which treatment was started in scientific trials.
For additional information: https://www.eisai.com/news/enews202647pdf.pdf
Copyright © 2026 JCN Newswire. All rights booked. A department of Japan Corporate News Network.